NuScale Breaks Below Bear Case as Cash Cushion Fails to Anchor Valuation

What happened

NuScale stock closed at $5.69 on Oct 19, its lowest since May 2024 and 89% below its October 2025 record, as the market continues to discount the absence of binding customer contracts despite a $1.9 billion cash position and no debt. The decline extends a prolonged slide from over $40 in mid-2025 to below the company's bear-case scenario of $7 per share, reflecting deepening skepticism about commercialization timelines. The cash balance, while substantial, is not a valuation floor because it is being consumed by operating losses and milestone payments tied to the non-binding ENTRA1 agreement, with 1H26 operating cash outflow of $372.9 million. Management's reliance on equity issuance to fund operations has expanded the share count to 410.4 million Class A shares, further pressuring per-share value even as liquidity remains ample. The Motley Fool article asks whether the stock is finally a buy, but it overlooks that the company had only $0.64 million in revenue in the first half of 2026 and no binding module delivery contract, leaving the investment case entirely dependent on future off-take agreements that have yet to materialize.

Implication

The stock trading at roughly 1.2 times cash per share ($4.63) suggests the market assigns minimal value to NuScale's regulatory approvals and supply-chain relationships, which could offer upside if a single binding PPA is signed; however, that outcome remains uncertain and the master report's WAIT rating still applies. The bear case of $7 appears to have already been breached, indicating the market is pricing in a high probability of continued non-binding discussions and further cash burn, so any investment requires a high tolerance for loss of capital. With $1.9 billion in cash and no debt, near-term insolvency risk is low, but the company burned $372.9 million in operating cash in the first half of 2026 alone, implying the runway is finite and additional equity raises are likely without revenue inflection. The article's focus on the cash balance is misleading because that cash is committed to funding ENTRA1 milestone payments and long-lead manufacturing, not available for shareholder returns, and per-share cash will decline as shares are issued. A prudent approach is to wait for evidence of a definitive TVA or Romania contract before considering entry, as the stock could fall further if dilution accelerates or if the partnership structure continues to consume cash without delivering backlog.

Thesis delta

The stock has fallen well below the bear-case scenario of $7 and now trades only slightly above per-share cash of $4.63, which on its face makes the downside more limited if the company can avoid further dilution. However, the core thesis remains unchanged: value hinges on converting regulatory lead into binding customer contracts, and the absence of any such contract after years of partnerships continues to undermine the investment case. The appropriate stance is still WAIT, but the entry point has become more tempting for risk-tolerant investors who believe a PPA is imminent; we would not upgrade to BUY without concrete evidence of off-take.